NCT05417776View on ClinicalTrials.gov

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2026

Conditions
Interstitial Lung Disease
Interventions
DRUG

[68Ga]CBP8

An injection of up to 350 MBq of \[68Ga\]CBP8 will be administered intravenously followed by PET-MRI.

DRUG

Dotarem

Dotarem will be administered during MRI portion of study.

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT05417776 - Collagen-targeted PET Imaging for Early Interstitial Lung Disease | Biotech Hunter | Biotech Hunter